Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginNet MarginOperating MarginReturn on Sales

Cogent Biosciences (COGT) EBT Margin (2017 - 2020)

Cogent Biosciences has reported EBT Margin over the past 4 years, most recently at 18325.64% for Q3 2020.

  • Quarterly results put EBT Margin at 18325.64% for Q3 2020, down 1714868.0% from a year ago — trailing twelve months through Jun 2021 was 31541.03% (down 3144383.0% YoY), and the annual figure for FY2025 was 10507.38%, changed.
  • EBT Margin for Q3 2020 was 18325.64% at Cogent Biosciences, down from 1401.52% in the prior quarter.
  • Over the last five years, EBT Margin for COGT hit a ceiling of 15.05% in Q4 2019 and a floor of 18325.64% in Q3 2020.
  • Median EBT Margin over the past 4 years was 327.26% (2017), compared with a mean of 1634.34%.
  • Peak annual rise in EBT Margin hit 29626bps in 2020, while the deepest fall reached -1714868bps in 2020.
  • Cogent Biosciences' EBT Margin stood at 319.41% in 2017, then increased by 29bps to 225.91% in 2018, then soared by 107bps to 15.05% in 2019, then plummeted by -121857bps to 18325.64% in 2020.
  • The last three reported values for EBT Margin were 18325.64% (Q3 2020), 1401.52% (Q2 2020), and 86.67% (Q1 2020) per Business Quant data.